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Abstract
Background: Recruitment to clinical trials can be challenging and slower than anticipated. This prospective patient
survey aimed to investigate the proportion of patients approached about a trial who agree to participate, their
motivations for trial participation and their views on aspects of cancer research.
Methods: Patients who had been approached about participation in any clinical trials in the Gastrointestinal and
Lymphoma Unit at the Royal Marsden were invited to complete a questionnaire. The statistical analysis is mainly
descriptive, with percentages being reported. Univariate logistic regression analysis was used to determine any
associations between patient characteristics and patient responses.
Results: From August 2013–July 2014, 276 patients received 298 clinical trial patient information sheets and were
asked to complete the questionnaire. The majority of patients (263 patients, 88 %) consented to a clinical trial and
249 of the 263 patients (95 %) completed the questionnaire. Multiple factors influenced decisions to participate in
clinical trials, with patients stating that the most important reasons were that the trial offered the best treatment
available and that the trial results could benefit others. Of the 249 questionnaire respondents, 78 % would donate
their tissue for genetic research, 75 % would consider participating in studies requiring a research biopsy and 75 %
felt that patients should be informed of trial results. Patients treated with palliative intent and those who had
received multiple lines of treatment were more willing to consider research biopsies. Of the patients approached
about a clinical trial of an investigational medicinal product, 48–50 % would have liked more information on the
study drugs/procedures.
Conclusion: The majority of patients approached about a clinical trial consented to one or more trials. Patients’
motivations for trial participation included potential personal benefit and altruistic reasons. A high proportion of
patients were willing to donate tissue for research and to consider trials involving repeat biopsies. The majority of
patients feel that participants should be informed of trial results and there is a group of patients who would like
more detailed trial information.
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Background
Recruitment to clinical trials can be challenging, leading
to 1 in 10 cancer trials registered on ClinicalTrials.gov
between 2005 and 2011 being closed prematurely due to
poor accrual and other trials taking longer than antici-
pated to complete recruitment [1–3]. This is a major
problem for oncologists, not only from a scientific per-
spective, but also due to the implications of failing to
meet recruitment targets. For example, in the United
Kingdom (UK), clinical trial performance metrics in-
clude meeting certain government targets, such as
recruiting the first study patient within 70 days of re-
ceiving a valid research application [4]. Although the UK
has one of the highest clinical trial participation rates in
the world, with more than 1 in 5 adult cancer patients
participating in clinical trials [5], the proportion of pa-
tients with whom cancer research is discussed ranges
from 10–61 % depending on the hospital trust [6].
Patients’ decisions regarding trial participation may be
influenced by the information they receive. Trials are be-
coming larger and increasingly complex, incorporating
translational research (including research biopsies),
adaptive designs and biomarker selection/stratification
[7, 8]. However, the level of scientific and health literacy
in the general population remains poor, with a third of
older adults in England having difficulty in reading and
understanding basic health-related information [9] and
previous studies have shown that patients can have mis-
conceptions about aspects of research, such as the risk
of side effects, the trial’s aims and the likelihood of per-
sonal benefit [10–12]. Therefore, there is concern that
clinical trial patient information sheets (PIS) may not be
fit-for-purpose. In addition, there are concerns that
mandatory research biopsies may deter patients from
participating in trials and, therefore, adversely affect trial
recruitment [13, 14].
A better understanding of patients’ motivations for
participating in cancer research and their opinions of
trial information and the consent process may lead to
changes that facilitate trial recruitment and improve
patient satisfaction with the recruitment process. We
therefore conducted a prospective patient survey of
patients treated at the Royal Marsden (RM) for gastro-
intestinal (GI) cancers or lymphoma in order to investi-
gate patients’ willingness to participate in clinical trials
and their views on aspects of cancer research.
Methods
The patient survey was approved by the Royal Marsden
Committee for Clinical Research and patients verbally
consented to participate in the survey. This survey was
designed as a ‘service evaluation’, to evaluate patients’ ex-
periences of clinical trials at our institution and thereby
investigate if aspects of this process could be improved.
Ethical review by an external review board was, there-
fore, not required. The primary endpoint was the pro-
portion of patients approached about a clinical trial who
agreed to participate in a trial. Secondary endpoints in-
cluded reasons why patients consented to/declined trials,
the proportion of patients who were happy to be
approached about participating in research, the propor-
tion of patients who would consider trials involving gen-
etic research or research biopsies and patients’ views of
the consent process, the trial information provided and
feedback of study results to participants.
Study subjects
All patients who had been approached about a trial be-
tween August 2013 and July 2014 in the GI and Lymph-
oma unit at the RM (a specialist cancer centre) were
eligible to participate in this patient survey. Clinical Tri-
als of an Investigational Medicinal Product (CTIMP)
and non-CTIMP trials were included, as well as pre-
screening studies. The CTIMP trials included trials
investigating targeted therapies, immunotherapies,
chemotherapy, the optimal duration of chemotherapy
and the scheduling of chemotherapy and surgery (e.g.
peri-operative chemotherapy versus post-operative
chemotherapy).
Patients were invited to participate in the survey by
the unit research nurses or doctors when they notified
staff about their decision regarding participation in a
trial. They were also informed that the survey aimed to
improve the experiences of patients with regards to clin-
ical trials and that participation in the survey was volun-
tary with no obligation to take part.
Questionnaires
Two paper questionnaires were developed based on a lit-
erature review and the authors’ experiences of trial re-
cruitment. The questionnaires were comprised of Likert,
multiple choice and free-text questions. Patients who
consented to a trial were given the 25-question Ques-
tionnaire A (Additional file 1), which included questions
on their reasons for deciding to participate in the trial.
Patients who declined a trial received the 21-question
Questionnaire B (Additional file 2), which included
questions regarding their reasons for declining the trial.
Patients who consented/declined more than one trial
were asked to complete one questionnaire per trial.
The questionnaires could be completed in clinic or
taken home and returned at the patients’ next clinic
appointment.
Each patient was allocated a unique survey ID number,
which was written on their completed questionnaires
and on a demographic sheet completed by the research
nurse looking after the patient. The researchers analys-
ing the survey responses were not able to identify the
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patients from their survey ID numbers. The question-
naire was, therefore, anonymous to the researchers ana-
lysing the survey results, unless the patient chose to
complete an optional section of the questionnaire and
provided their details so that they could be contacted
about future surveys.
SYM and CM compared patients’ free-text answers to
the question: ‘what type of cancer do you have?’, with the
data collected on the demographic sheet and scored the
answers as being correct if the patient had clearly identi-
fied the site of their primary tumour.
Collection of demographic and trial-related information
Demographic information was collected by research
nurses from patients’ electronic medical records. So-
cial class was characterised according to the National
Readership Survey (NRS) classification [15] by SYM
and CM according to the patients’ recorded occupa-
tion. The percentage of households in poverty in the
patients’ postcode area was determined using data
available from the Office for National Statistics, UK
[16], and used as a marker of social deprivation. Data
on clinical trial characteristics, PIS characteristics,
whether the patient agreed to complete the question-
naire and subsequent trial registration (including rea-
son for trial ineligibility) was also recorded.
Statistical analysis
The majority of the statistical analysis is descriptive, with
percentages being reported. The statistical analysis was
performed using Stata v13.1 (StataCorp, College Station,
TX, USA). Univariate logistic regression analysis was
used to determine any associations between patient
characteristics and patient responses and between trial
characteristics and PIS features. Patient characteristics
included in the univariate analysis were age, gender, per-
formance status (PS), number of previous lines of treat-
ment, previous trial participation, aim of treatment
(curative versus palliative) and type of trial.
Results
Clinical trial portfolio and patient recruitment
Between August 2013 and July 2014, 36 trials re-
cruited one or more patients (see Table 1). Two hun-
dred and seventy-six patients received 298 PIS for a
clinical trial (271 GI, 27 lymphoma), with 257 pa-
tients receiving 1 PIS, 16 patients receiving 2 PIS and
3 patients receiving 3 PIS. Patient demographics are
shown in Table 2. Two hundred and sixty-three pa-
tients (88 %) consented to a trial and 249 (95 %) of
these 263 patients completed the questionnaire (see
Fig. 1). Ten patients were ineligible for the trial at
the time they returned for consent (e.g. due to
clinical deterioration) and were, therefore, ineligible
for the patient survey.
Reasons for trial ineligibility
Thirty-eight (14 %) of the 263 patients who consented
to a clinical trial were not subsequently registered for
the trial, including 36 (36 %) of the 101 patients who
Table 1 Characteristics of trials in the Gastrointestinal and
Lymphoma Unit (n = 36)
Trial characteristic Number of trials (%)
(n = 36)
Study type
CTIMP 24 (67 %)
Non-CTIMP 9 (25 %)
Pre-screening 3 (8 %)
Sponsor
Royal Marsden 9 (25 %)
Other academic institution 11 (31 %)
Pharmaceutical company 16 (44 %)
Phase
I 2 (6 %)
II 10 (28 %)
II/III 2 (6 %)
III 13 (36 %)
Not applicable 9 (25 %)
Trial setting
Neoadjuvant 3 (8 %)
Adjuvant 3 (8 %)
Advanced 16 (44 %)
Any 5 (14 %)
Lymphomaa 9 (25 %)
Randomised trial
Yes 20 (56 %)
No 16 (44 %)
Molecular screening
Yes 10 (28 %)
No 26 (72 %)
Number of PIS (e.g. separate pharmacodynamics
or imaging sub-studies)
1 20 (56 %)
2 11 (31 %)
3 4 (11 %)
5 1 (3 %)
Key: CTIMP = Clinical Trial of an Investigational Medicinal Product, pre-
screening =molecular pre-screening to determine potential eligibility for a
specific CTIMP study, PIS = patient information sheet
aLymphoma trials were considered separately as the intent of lymphoma
treatment is to induce remission and, therefore, the treatment paradigms
differ from that of gastrointestinal malignancies
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consented to CTIMP/pre-screening trials. The main
reason for trial ineligibility was that their molecular
profile (e.g. human epidermal growth factor receptor
2 (HER2) status) did not meet the study requirements
(n = 22). Other reasons for patient ineligibility in-
cluded: no available tissue for molecular testing (n =
3), further investigations revealed a change in disease
extent: e.g. from localised to metastatic disease (n =
3), blood results outside of a specific range (n = 3),
deterioration in PS (n = 2) and non-measurable dis-
ease on imaging (n = 1).
Reasons for trial participation
Multiple factors influenced patients’ decisions to partici-
pate in a clinical trial (see Table 3). When patients were
asked to indicate their main reason for trial participation,
a belief that ‘the trial offered the best treatment available’
or that ‘the trial results could benefit others’ were the
most frequent responses (see Fig. 2). A univariate analysis
was used to determine any associations between patient
characteristics and patients’ main reason for trial partici-
pation. Patients were more likely to state that their main
reason for participation was ‘the trial offered the best
treatment available’, if they were being treated with pallia-
tive rather than curative intent (33 % versus 19 %, odds
ratio 2.11, 95 % CI 1.09–4.08, p = 0.026), had a worse PS
(19 % for PS 0, 34 % for PS 1, odds ratio 2.12, 95 % CI
0.97–8.79, p = 0.027) or had not previously participated in
a clinical trial (32 % (no) versus 8 % (yes) for previously
participated, odds ratio 5.14, 95 % CI 1.51–17.5, p =
0.009). Patients were more likely to state that their main
reason for participation was ‘the trial results could benefit
others’ if they were < 65 years compared to ≥ 65 years
(64 % versus 39 %, odds ratio 2.77, 95 % CI 1.62–4.74, p <
0.001), being treated with curative rather than palliative




Male 188 (68 %)
Female 88 (32 %)
Age
Median (range) 64 years (19–
85)
Native English speaker 252 (91 %)
Ethnicity
White 238 (86 %)
Asian 21 (8 %)
Black 8 (3 %)
Other 9 (3 %)
Marital status
Married/partner 194 (70 %)
Single 35 (13 %)
Separated/divorced 15 (5 %)
Widowed 14 (5 %)
Unknown 18 (7 %)
Social class
Grade A/B (upper middle/middle class) 56 (20 %)
Grade C1/2 (lower middle/skilled working class) 34 (12 %)
Grade D (working class) 48 (17 %)
Grade E (retired) 109 (40 %)
Grade E (unemployed) 5 (2 %)
Unknown 24 (9 %)
Percentage of households in poverty in the patient’s
postcode area
≥ 27.61 % 20 (7 %)
22.01–27.6 % 43 (16 %)
17.91–22 % 48 (17 %)
14.41–17.9 % 51 (18 %)
≤ 14.4 % 112 (41 %)
Not in Englanda 2 (1 %)
Type of cancer
Colorectal 117 (42 %)
Oesophagogastric 100 (36 %)
Pancreatic 18 (7 %)
Hepatobiliary 11 (4 %)
Carcinoma of unknown primary/other GI 3 (1 %)
Hodgkin’s lymphoma 10 (4 %)
Non-Hodgkin’s lymphoma 17 (6 %)
Treatment aim
Curative 96 (35 %)
Palliative 180 (65 %)
Table 2 Patient demographics (Continued)
Number of previous lines of treatment
0 133 (48 %)
1 87 (32 %)
2 39 (14 %)
3 13 (5 %)
≥ 4 3 (1 %)
Unknown 1 (1 %)
Performance status
0 106 (38 %)
1 130 (47 %)
2 20 (7 %)
3 3 (1 %)
Unknown 17 (6 %)
aNo comparable poverty statistics available for regions outside of England
GI gastrointestinal
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intent (63 % versus 47 %, odds ratio 1.97, 95 % CI 1.23–
3.46, p = 0.017) or had previously participated in a clinical
trial (72 % (yes) versus 50 % (no) for not participated, odds
ratio 2.65, 95 % CI 1.21–5.83, p = 0.012). Gender and
number of previous lines of treatment did not significantly
influence patients’ main reason for trial participation.
Patients who declined a clinical trial
Ten of the 25 patients who declined a clinical trial
completed the questionnaire. There was no pattern to
the types of trial declined and no demographic differ-
ences between the patients who consented and those
who declined. Reasons for declining a trial included:
unwillingness to take the study drug/placebo or have
additional research procedures, decision not to have
any further treatment, general anxiety about cancer
diagnosis/treatment and a belief that the standard
treatment was more effective. Nine of the 10 patients
stated that they were glad to have been approached
about participating in cancer research.
Patients’ views on cancer research and biopsies
Two hundred and twenty-one patients (96 %) who
completed Questionnaire A were happy to have been
approached about participating in cancer research and
225 out of 228 patients (99 %) believed that cancer
research would help doctors better understand and
treat cancer.
Fifteen patients (7 %) agreed/strongly agreed, 43
patients (19 %) were neutral and 164 patients (74 %)
disagreed/strongly disagreed with the statement:
Fig. 1 Recruitment to clinical trials and the patient survey
Table 3 Factors which influenced patients’ decision to participate in a clinical trial
Reason CTIMP Pre-screening Non-CTIMP All
N (%) N (%) N (%) (n = 241)
(n = 63) (n = 28) (n = 150)
Patient felt the trial offered the best available treatment 49 (78 %) 16 (57 %) 57 (39 %) 122 (51 %)
Patient felt the trial result could benefit others 53 (84 %) 24 (86 %) 143 (96 %) 220 (92 %)
Patient wanted to contribute to scientific research 37 (59 %) 16 (57 %) 111 (74 %) 164 (68 %)
Patient felt they would be monitored more closely 28 (44 %) 9 (32 %) 42 (28 %) 79 (33 %)
Patient felt they would have better quality care 20 (32 %) 5 (18 %) 24 (16 %) 49 (20 %)
Patient’s family were keen for patient to participate 24 (38 %) 8 (29 %) 20 (13 %) 52 (22 %)
Patient trusted the doctor treating them 38 (60 %) 10 (36 %) 73 (49 %) 121 (50 %)
Patient felt that otherwise their cancer will get worse 17 (27 %) 3 (11 %) 13 (9 %) 33 (14 %)
Other reason 4 (6 %) 0 (0 %) 8 (5 %) 12 (5 %)
Key: CTIMP = Clinical Trial of an Investigational Medicinal Product, pre-screening =molecular pre-screening to determine potential eligibility for a specific
CTIMP study
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‘I have concerns about the use and storage of blood
and tissue samples for research’. Regarding genetic
research, 173 patients (78 %) agreed/strongly agreed,
25 patients (11 %) were neutral and 25 patients
(11 %) disagreed/strongly disagreed with the state-
ment: ‘I would agree to donate tissue for genetic re-
search even if I was not told my genetic results’.
In response to the question: ‘would you participate
in a trial that required you to have a repeat biopsy?’
78 patients (34 %) answered ‘yes’, 95 patients (41 %)
answered ‘maybe’, 48 patients (21 %) answered ‘no’
and 10 patients (4 %) did not answer the question.
The results of a univariate analysis of patient factors
and their association with patients’ views of research
biopsies is shown in Table 4.
Patients’ understanding of their cancer diagnosis
One hundred and eighty-three patients (79 %) correctly
stated their diagnosis, 14 patients (6 %) wrote an incor-
rect answer (mainly indicating a metastatic site as their
type of cancer) and 34 patients (15 %) did not answer
the question. Patients under the age of 65 years were
more likely to answer the question correctly (87 % ver-
sus 71 %, odds ratio 2.69, 95 % CI 1.38– 5.25, p = 0.004).
Patients’ views on the written trial information
The mean PIS length was 17 pages (median 4 pages,
range 3–50 pages) and was influenced by trial type
(CTIMP: 23 pages, non-CTIMP: 8 pages, pre-
screening: 5 pages, p < 0.001). Two hundred and fif-
teen patients (90 %) felt the PIS was easy to under-
stand and 22 patients (9 %) felt the PIS was too long
(see Fig. 3). One patient admitted to not having read
the information. There was a poor correlation be-
tween PIS length and patients’ views on whether the
PIS was too long (see Fig. 4). All 10 patients who de-
clined a study and completed the questionnaire be-
lieved the PIS was easy to understand and none of
these patients felt the PIS was too long.
Patients’ views on the content of the PIS are shown
in Fig. 5. Thirty-six patients (15 %) looked up add-
itional information about the trial (CTIMP: 32 %,
pre-screening: 14 %, non-CTIMP: 7 %). Some patients
wrote free-text comments requesting additional infor-
mation: e.g. ‘more stats on the progress of the trial’
and ‘I found reading the actual trial protocol particu-
larly useful’.
Patients’ views on the verbal explanation, trial discussions
and the consent process
The verbal explanation of the trial was rated as excel-
lent, good, fair or poor by 100 (40 %), 124 (50 %), 14
(6 %) and 1 (0.4 %) patients respectively. All 10 pa-
tients who declined a study and completed the ques-
tionnaire rated the verbal explanation as excellent/
good.
Two hundred and nineteen patients (88 %) discussed
the trial with 1 or more people (CTIMP: 97 %, pre-
screening: 96 %, non-CTIMP: 83 %), usually a family
member (see Table 5). Two hundred and thirty-one
patients (93 %) felt they had been given enough time to
consider whether they wished to participate in the trial.
Twenty-two pre-screening trial patients (79 %), 103 non-
Fig. 2 The main reason that motivated patients to participate in a clinical trial. Key: CTIMP = Clinical Trial of an Investigational Medicinal Product,
pre-screening =molecular pre-screening to determine potential eligibility for a specific CTIMP study
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CTIMP trial patients (66 %) and 35 CTIMP trial patients
(54 %) would have been willing to consent to the trial on
the same day they received the PIS.
Feedback of study results
One hundred and seventy-three patients (75 %) felt
patients should be told trial results, 13 patients (6 %)
felt they should not be told and 40 patients (17 %)
were unsure. A higher proportion of CTIMP trial pa-
tients felt participants should be told trial results
(88 % versus 68 % for non-CTIMP trials, odds ratio
3.29, 95 % CI 1.46–7.45, p = 0.004). One hundred and
ten patients (52 %) felt results should be provided by
post, 91 patients (42 %) felt these should be discussed
in clinic, 33 patients (16 %) thought via a website and
2 patients added free-text comments suggesting via
Email.
Discussion
The majority of patients in our survey were happy to be
approached about participating in cancer research and
were keen to participate in clinical trials. We chose to
develop our own survey as existing surveys, such as the
UK National Cancer Experience Survey, cover a broad
range of topics and only include a few questions on clin-
ical trials. Although our survey was less well-validated, it
allowed us to determine the proportion of patients who
consented to a clinical trial as well as investigate
Table 4 Univariate analysis of factors influencing patients’ views on whether they would participate in a trial involving a research
biopsy






< 65 years 37 (57 %) 1.0
≥ 65 years 41 (67 %) 1.55 (0.75–3.21) 0.236
Gender
Male 59 (64 %) 1.0
Female 19 (56 %) 0.71 (0.32–1.58) 0.398
Tumour type
Colorectal 30 (60 %) 1.0
Oesophagogastric 37 (73 %) 1.76 (0.76–4.06) 0.184
Performance status (PS)
0 30 (67 %) 1.0
1 36 (59 %) 0.72 (0.32–1.61) 0.423
2 7 (70 %) 1.17 (0.26-5.16) 0.839
Previously participated in a clinical trial
Yes 13 (65 %) 1.0
No 64 (61 %) 1.19 (0.44–3.23) 0.733
Number of previous lines of treatment
0 24 (47 %) 1.0
1 31 (67 %) 2.33 (1.02–5.31) 0.045
2+ 22 (79 %) 4.13 (1.43–11.9) 0.009
Type of treatment
Palliative 60 (69 %) 1.0
Curative 18 (46 %) 0.39 (0.18–0.84) 0.015
CTIMP
No 44 (60 %) 1.0
Yes 19 (53 %) 0.74 (0.33–1.65) 0.457
ap values compare the proportion of patients who answered ‘yes’: e.g. 67 % for PS0 versus 59 % for PS1 and 70 % for PS2
Key: CTIMP = Clinical Trial of an Investigational Medicinal Product, pre-screening =molecular pre-screening to determine potential eligibility for a specific
CTIMP study
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patients’ views on cancer research in more detail. Re-
assuringly, our results were consistent with the UK Na-
tional Cancer Experience Survey, which reported that
95 % of patients who had research discussed with them
were happy to have been asked and 53 % of patients with
whom research was not discussed would have been
happy to have been asked [17]. However, patients who
have just started their first treatment for cancer are less
likely to participate in cancer research and it appears
that as time increases from diagnosis, patients are more
positive about engaging with research [6, 18]. This may
reflect the availability of clinical trials, but may also be
influenced by factors such as the psychological impact of
a recent cancer diagnosis. Patients were particularly will-
ing to consent to non-CTIMP trials, possibly due to the
less interventional nature of these studies. We had ori-
ginally planned to compare the characteristics of the pa-
tients who consented to a trial with those who declined
a trial, but this was not possible due to the small number
of patients who declined a trial.
However, although a high proportion of patients con-
sented to a trial, 36 % of patients subsequently failed
screening for CTIMP/pre-screening trials. Screen fail-
ures may become increasingly problematic due to the
growing number of biomarker selected/stratified trials.
Twenty-eight percent of our trial portfolio involved tis-
sue analysis prior to patient randomisation (either to de-
termine eligibility or for stratification), resulting in 66 %
of screen failures being caused by patients’ molecular
profiles or a lack of tissue for analysis. This has import-
ant logistical and workload implications, as staff time is
required for trial set-up, patient recruitment and speci-
men coordination, even though many patients are subse-
quently ineligible for the trial.
In agreement with other studies, we found that pa-
tients’ decisions to participate in research are influenced
by multiple factors including altruism, trust in their
treating physician and beliefs that they would receive su-
perior treatment, closer monitoring and better quality
care [11, 12, 19–23]. However, the ‘most important’ rea-
son varied according to factors such as trial type and
treatment intent. Although 52 % of patients consenting
to CTIMP trials were motivated by a belief that the trial
was the best treatment option available, 25 % of patients
participated for altruistic reasons. Interestingly, 15 % of
non-CTIMP trial respondents felt that the trial offered
the best treatment available. For some trials (e.g. mo-
lecular profiling trials), this was a logical response. How-
ever, other trials had no direct patient benefit and,
therefore, some patients seem to have misunderstood
the trials’ aims. Other studies have shown that patients
can misunderstand the potential personal benefit from
clinical trials [13, 20] and it is important to ensure that
patients clearly understand the purpose of any trial and
any trial-related procedures.
Translational research is increasingly important and
patients’ opinions of tissue and genetic research should
be considered by researchers and ethics committees
when assessing translational research protocols. Reassur-
ingly, only 7 % of our patients had concerns about the
use and storage of blood/tissue samples for research,
and indeed, many patients strongly felt that this was not
Fig. 3 Patients’ views on the length and readability of the patient information sheet
Fig. 4 Relationship between patient information sheet (PIS) length
and patients’ views on PIS length
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an issue. This is supported by the results of other stud-
ies, which demonstrate that the majority of cancer pa-
tients would allow the use of their tissue for research
[13, 24, 25]. In our survey, 78 % of patients would agree
to donate tissue for genetic research, even if they were
not told their genetic results, indicating patient support
for genomic research into cancer. However, these results
should be interpreted with caution as no information
was provided in our questionnaire regarding the poten-
tial implications of genetic results, so patients’ under-
standing and knowledge of any potential issues is
unknown.
Biopsies are becoming an increasingly common com-
ponent of clinical trials and 42 % of our trials involved
an optional or mandatory biopsy. There have been
ethical concerns about mandatory research biopsies: e.g.
a lack of alternative treatment options and patients’
understanding of biopsy risks and the purpose of the
biopsy [14, 26–28]. Although some patients would not
participate in trials involving a biopsy, it is important to
highlight that 75 % of our patients stated they would
consider participating in a trial involving a repeat biopsy.
This is significant as staff and ethics committee assump-
tions regarding patients’ attitudes to biopsies may not be
accurate. For example, a survey of patients, medical on-
cologists and Institutional Review Board (IRB) members
on the issue of mandatory research biopsies demon-
strated that oncologists and IRB members may over-
estimate the anxiety associated with biopsies and that
patients would accept a higher risk of biopsy-related
complications than oncologists/IRB members [13]. Fur-
thermore, staff may be reluctant to discuss biopsies with
older-aged patients or patients with a poorer PS due to
assumptions that these patients would not wish to
undergo any additional procedures. Interestingly, age
and PS did not significantly impact on the willingness of
our patients to consider a biopsy and we feel that these
factors need not be a barrier to discussing biopsies with
patients, allowing them to make their own decisions.
Patients being treated with palliative intent and pa-
tients who have received more lines of treatment appear
Fig. 5 Patients’ views on the amount of information provided in the patient information sheet. Key: CTIMP = Clinical Trial of an Investigational
Medicinal Product




Spouse/partner 171 (68 %)
Son/daughter 64 (26 %)
Sibling 56 (23 %)
Friend 37 (15 %)
Parent 16 (6 %)
GP 13 (5 %)
Grandchild 7 (3 %)
Othera 11 (4 %)
aOther included: other family members, work colleague/boss, other doctors,
Macmillan nurse, nutrition advisor/mind coach and their insurance company.
Many patients discussed trial participation with more than one person
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to be more willing to consider a repeat biopsy. This
could be due to a number of reasons, including willing-
ness to participate in anything that could potentially
benefit them, increasing altruistic motives or a better
understanding of cancer and its treatment. Patients with
a recent diagnosis of cancer are often keen to start treat-
ment as soon as possible, and may be deterred by con-
cerns regarding potential biopsy-related delays, may feel
psychologically overwhelmed by their diagnosis and, as
previously mentioned, are less likely to engage in re-
search [18]. However, these results should be interpreted
with caution due to the small number of patients in the
subgroup analyses and because trials in more advanced
lines of treatment were more likely to contain a biopsy
component. Further research is needed into patients’
views on biopsies, particularly as it has been suggested
that previous negative biopsy experiences may discour-
age patients from future biopsies [29].
Lengthy trial information can be off-putting to patients
[22] and healthcare staff may feel that patients are over-
whelmed by the amount of information provided, par-
ticularly as they have often also received information
about their cancer and their standard treatment options.
In addition, lengthy trial information can lead to a poor
recall of risks and it has been suggested that shorter in-
formation leaflets might lead to better informed consent
[30]. Indeed, one patient admitted to not having read the
PIS, and this is not unique to our study [31]. PIS are
often reviewed/tested by patients prior to submission to
ethics committees, and this can result in amendments to
their wording and layout that make the final version
easier to understand [32]. However, even though the
average PIS length was 17 pages, 55 % of patients clearly
stated they did not feel it was too long and 48–50 % of
patients approached about CTIMP studies would have
liked more information on the study drugs/procedures.
Therefore, there does seem to be a group of patients
who wish to know more details about the trial, and in-
deed many of the free-text comments expressed a desire
for more detailed information. The majority of patients
discussed the trial with family members, and so patients’
relatives may also wish to have more detailed trial
information.
However, approximately 20–28 % of our patients did
not want more information on the trial drugs/proce-
dures and other studies have shown that patients feel
that the amount of information provided is sufficient
[11]. A one-size-fits-all approach is, therefore, unlikely
to suit the needs of every patient, and strategies to tailor
information according to the individual patient’s wishes
should be explored. Fifteen percent of patients looked
up additional information (rising to 32 % for CTIMP
studies) and, therefore, one strategy could be to provide
a link in the PIS to a website containing further trial
information. This would have the advantage of providing
a resource for interested patients without overloading
patients who are satisfied with the level of information
already provided.
Patients who enrol quickly into clinical trials may not
feel that they fully understand the implications of trial
participation [33] and, therefore, ethics applications may
state that patients will be given at least 24 hours to con-
sider the information provided. However, some patients
find it inconvenient to return specifically to sign consent
and do not wish to delay screening procedures/treat-
ment. This can be a particular issue for pre-screening
trials, which involve biomarker testing of archival tissue
to identify patients who might be eligible for corre-
sponding CTIMP trials. As 79 % of patients approached
about pre-screening trials would have been willing to
consent on the same day as receiving the PIS, perhaps
patients who wish to consent on the same day should be
able to do so (with the important caveat of ensuring pa-
tients do not feel pressurised into signing consent).
Although 75 % of patients in our survey (rising to
89 % for CTIMP trials) felt participants should be in-
formed of trial results, these are not always effectively
communicated to patients. The question was specifically
worded to highlight the fact that results may not be
available for many years, although it did not directly
state that patients may be deceased at the point when
final study results are available. Our results are compar-
able to those from other studies [22, 34–36], indicating
that the majority of patients feel they should be offered
the trial results, not only for their personal interest and
satisfaction, but also out of respect for their contribution
to the trial [22]. One of the concerns regarding the feed-
back of trial results is the potential for psychological dis-
tress (e.g. due to randomisation to an arm with inferior
outcomes) [35, 36]. However, although receiving results
can be distressing [37, 38], this does not necessarily lead
to regret at receiving results and some patients sug-
gested that the satisfaction of knowing the results out-
weighed the potential distress of hearing bad news [36].
Indeed, one study demonstrated that 84 % of patients
would like to receive results from a negative trial [36]
and receiving study results may improve participants’
research experience [39]. Furthermore, not receiving
results may deter patients from participating in future
trials [34].
However, the optimal content, timing and method of
providing results to participants is currently unclear,
with our patients being divided as to whether results
should be provided in clinic or via a letter. Some pa-
tients wish to know their personal results, others want
the overall study results and many wish to know both
[36]. In addition, patients are keen to receive regular up-
dates on the trial’s progress [22, 36, 40]. Many sponsors
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provide participating sites with newsletters providing
progress updates, so one strategy could be to provide a
lay version of these newsletters to interested patients as
well as a lay summary when the results are available.
When considering the applicability of our results to
other patient populations, there are a number of factors
that should be considered. Firstly, the structure of the
UK health service (which is not dependent on patients’
health insurance) may facilitate trial participation [41].
Secondly, our patients were predominantly white,
middle-class men with low levels of social deprivation.
Although we did not specifically assess the educational
level or health literacy of our patients, it is likely that
our patients are more highly educated than patients
from more deprived socioeconomic backgrounds, and
issues such as lack of support, financial worries and
difficulties with transport may be less problematic for
our patients in comparison to patients from socially de-
prived areas [42]. Despite this, it is concerning that 21 %
of patients either did not correctly state their diagnosis
or left this question blank. It is uncertain whether the
patients who did not answer the question accidentally
missed the question or did not know what to write. If
patients have not accurately understood their diagnosis,
then they are less likely to fully understand the trial
information. In addition, this survey only included pa-
tients with GI malignancies or lymphoma, and their
views (particularly on biopsies) may differ from patients
with other types of cancer. Also, the trial portfolio was
heterogeneous in nature and the characteristics of the
individual trials (e.g. palliative versus curative, study
phase) and PIS may have influenced patients’ responses.
In addition, whether patients’ answers to the question-
naire truly reflect their views on the PIS is uncertain.
Patients’ responses may be influenced by ‘social desir-
ability’: i.e. they may give a socially desirable response if
they know someone else will read their answers [43].
Furthermore, patients may falsely believe they have
understood the PIS. For example, 93 % of patients in
one phase I study stated they understood most or all of
the information provided, but only 33 % were able to
state the purpose of the trial in which they were partici-
pating [12]. Additionally, some of the questions were
hypothetical in nature for some patients, as they were
not relevant to the type of trial for which they had
received a PIS and this may have influenced their
responses.
However, it is important to highlight that although
RM is a specialist cancer centre and patients referred
from elsewhere in the UK for consideration of clinical
trials may be more motivated to participate in cancer re-
search, the majority of patients in our survey lived lo-
cally and were not referred to RM specifically for a trial.
In addition, one of the main strengths of this survey is
that a high proportion of patients who consented to a
trial also completed the questionnaire (thereby minimis-
ing any potential bias between questionnaire responders
and non-responders).
Conclusions
In summary, this survey provides an insight into the
views of patients on cancer research. The majority of
patients were happy to have been approached about
participating in clinical trials, and only a small propor-
tion of patients declined a clinical trial. Although a
major motivating factor was the possibility of improving
their own treatment, many patients were also keen to
help others and to contribute to scientific research. This
extends to the use of tissue samples for research and to
the consideration of research biopsies. We recommend
that clinical trials and research biopsies are discussed
with potentially eligible patients (including older-aged
patients), to provide interested patients with the oppor-
tunity to participate in research. New strategies for tai-
loring the information needs to the individual patient,
methods for disseminating trial results to participants
and incorporating options for feedback of results into
the initial trial consent process should be considered.
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